Your shopping cart is empty

Subscriber login

Advanced Search

Return to the main site

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > J&J Receives Complete Response on Xarelto for Acute Coronary Syndrome

Drug Industry Daily

June 25, 2012 | Vol. 11 No. 124

J&J Receives Complete Response on Xarelto for Acute Coronary Syndrome

The FDA has given Johnson & Johnson (J&J) a complete response letter for its sNDA on the blood-clot drug Xarelto following a narrow advisory committee rejection last month.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Concerns with CMO Draw CRL for Allergan’s Levadex FDA: Hemispherx Must Complete At Least One More Ampligen Trial Impax’s Parkinson’s Drug NDA Rejected Due to Manufacturing Issues FDA Nixes Cornerstone Low-Sodium Drug, Asks for More Clinical Info

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.